# Aureka Biotechnologies

> AI-native TechBio building biological foundation models with closed-loop wet-lab infrastructure.

## Why it is interesting

$100M Series B (Aug 2026, ~$200M cumulative) to scale AuraIDE — models that improve from proprietary Lab-in-the-Loop experiments, not only public protein datasets.

## Profile

- **Stage:** series-b
- **Status:** private
- **Industries:** biotech-life-sciences, ai-ml, healthtech
- **Coverage:** full
- **Last updated:** 2026-08-11

## Key facts

- Series B (Aug 2026): $100M; ~$200M cumulative (PR Newswire)
- First tranche: Granite Asia (exclusive); later tranche led by undisclosed strategic; HLC, MPCi, NRL follow-on
- Products: AuraIDE foundation model; OpenDDE open-source; Lab-in-the-Loop platforms
- Tens of millions revenue over ~2 years from discovery partnerships (company)
- No VCT /fund/ IDs yet for Granite Asia / HLC / MPCi / NRL — names press-sourced

## Related articles

- https://venturecapitaltracker.com/2026-aureka-biotechnologies-100m-series-b-bio-foundation-models
- https://venturecapitaltracker.com/2026-august-10-11-investment-news-defense-optics-commerce

---
Source: https://venturecapitaltracker.com/startup/aureka-biotechnologies